Kypha

Kypha Inc. has discovered, developed, and commercialized innovative in vitro diagnostic biomarker tests in the fields of inflammation and autoimmune diseases. These tests are applicable to a wide range of indications, including: lupus, stroke, traumatic brain injury, preeclampsia, infections, nephropathy/renal disease, and transplant rejection. Potential impacts include early detection of adverse events, early optimization of treatment, more accurate prediction of outcomes, and more effective management of diseases and patients. Based on the ability to measure complement activation in the body, the company has developed a point-of-care platform called "COMP ACT," which provides real-time results to physicians.